stimulates mesangial cells to synthesize specific proteins, including a non-pancreatic (Type II) phospholipase A2 (PLA2). We have studied the regulation of PLA2 by proinflammatory mediators, implicated in the pathogenesis of glomerulonephritis, and have assessed whether the activation of second messenger systems modulates or mimics PLA2 gene expression by cytokines. IL-1 alpha and beta, TNF alpha, and LPS, but not serum, IL-2, or PDGF, potently induce PLA2 mRNA, and enzyme expression. IL-1-stimulated mesangial cells express a 1.0 kB PLA2 mRNA transcript that is induced in a dose-and time-dependent manner. IL-1-stimulated increases in steady-state PLA2 mRNA abundance result from a moderate increase in PLA2 transcription rate that is amplified by the prolonged persistence of the transcript. Forskolin and dibutyryl cAMP potentiate IL-1-induced PLA2 mRNA and enzyme expression, but have no effect in the absence of cytokine. 12-tetradecanoyl phorbol 13-acetate, sn-1, 2-dioctanoyl glycerol or 1-oleoyl-2-acetyl-snglycerol fail to induce PLA2 expression or to alter the effect of IL-1 when coincubated with the cytokine. In contrast, serum deprivation for 24 h specifically enhances IL-1-stimulated PLA2. Genistein potentiates PLA2 mRNA expression in cells exposed to both IL-1 and serum. The inhibitory effect of serum on IL-1-induced PLA2 mRNA abundance is reproduced by PDGF but not dexamethasone. These data demonstrate that the signaling pathways directly engaged by IL-1 to induce PLA2 expression in mesangial cells […] Abstract IL-1 stimulates mesangial cells to synthesize specific proteins, including a non-pancreatic (Type II) phospholipase A2 (PLA2). We have studied the regulation of PLA2 by proinflammatory mediators, implicated in the pathogenesis of glomerulonephritis, and have assessed whether the activation of second messenger systems modulates or mimics PLA2 gene expression by cytokines. IL-la and ,B, TNFa, and LPS, but not serum, IL-2, or PDGF, potently induce PLA2 mRNA, and enzyme expression. IL-l-stimulated mesangial cells express a 1.0 kB PLA2 mRNA transcript that is induced in a dose-and time-dependent manner. IL-i-stimulated increases in steady-state PLA2 mRNA abundance result from a moderate increase in PLA2 transcription rate that is amplified by the prolonged persistence of the transcript. Forskolin and dibutyryl cAMP potentiate IL-i-induced PLA2 mRNA and enzyme expression, but have no effect in the absence of cytokine. 12-tetradecanoyl phorbol 13-acetate, sn-i, 2-dioctanoyl glycerol or 1-oleoyl-2-acetyl-sn-glycerol fail to induce PLA2 expression or to alter the effect of IL-1 when coincubated with the cytokine. In contrast, serum deprivation for 24 h specifically enhances IL-i-stimulated PLA2. Genistein potentiates PLA2 mRNA expression in cells exposed to both IL-1 and serum. The inhibitory effect of serum on IL-i-induced PLA2 mRNA abundance is reproduced by PDGF but not dexamethasone. These data demonstrate that the signaling pathways directly engaged by IL-1 to induce PLA2 expression in mesangial cells interact with several second messenger systems in a cell-specific manner. We speculate that IL-1 induces specialized changes in mesangial cell structure and function through direct activation of a transcription factor(s), that result in induction of a specific gene set. (J.
Introduction
The mesangial cell occupies a central anatomical position within the glomerulus ( 1, 2) . Historically this cell has been regarded as unifunctional, only being important in the regulaThis work was presented in part at the annual meeting ofthe American Society of Nephrology, 2-5 December 1990, Washington, DC.
Address correspondence to Dr. John R. Sedor, Division ofNephrology, MetroHealth Medical Center, 2500 MetroHealth Drive, Office R-338, Cleveland, OH 44109-1998. Receivedfor publication 23 June 1992 and in revisedform 16 July 1993. tion ofglomerular filtration rate. However, in vitro and in vivo evidence suggests that the mesangial cell both produces and responds to biological modifiers and participates in the destructive and restorative processes that follow the initiation of glomerular injury ( 1, 2) . Intraglomerular expression of the cytokines, IL-1 and TNF a l has been demonstrated in both human and experimental glomerulonephritis (3, 4) . IL-1 and TNF activate the mesangial cell in culture to express new structural and functional characteristics in part by inducing expression of specific genes (3, 4) . IL-1 a, IL-I 3, and TNF stimulate release of the neutrophil chemotactic intercrine, , and IL-6 (6, 7) and regulate expression ofgenes controlling extracellular matrix synthesis and turnover (3, 4, 8) . We have demonstrated in rat mesangial cells that IL-1 a directly stimulates prostaglandin synthesis by increasing phospholipase A2 (PLA2)l activity through synthesis of a nonpancreatic (Type II) PLA2 (9) . The increases in PLA2 activity and PLA2 mRNA expression are coordinate and follow the same time course as cytokine-stimulated PGE2 synthesis.
As a result of these and other studies, many investigators have hypothesized that TNF-and IL-1-stimulated mesangial cells express an altered phenotype that contributes to glomerular injury. The intracellular events that mediate the cytokineinduced transition of mesangial function are poorly understood. This process involves induction ofa specific gene set by a network of short-term signals generated by interaction of the cytokine with the binding domain ofits receptor. The cytosolic signals generated by IL-1 and TNF in the mesangial cell have been fairly well defined. We and others have shown that IL-1 a rapidly stimulates 1, 2-diacylglycerol and phosphatidic acid formation ( 10, 11 ) but does not induce rapid changes in cystolic Ca>2 or pHi (10) . Both IL-1 and TNF cause phosphorylation of mesangial cell proteins, but neither cytokine increases the phosphorylation of the putative 80 kD substrate of protein kinase C (3, 12) . Pfeilschifter shows no increase in cAMP accumulation in response to IL-1 ( 13) , and TNF and IL-1 only stimulate cGMP formation after 4 to 6 h ( 14, 15) .
We have used the induction of PLA2 mRNA expression by IL-1 as a model system to define whether these early signals are converted to long-term changes in cell phenotype through induction ofspecific genes. Our studies suggest that the signalling pathways directly engaged by IL-I in the mesangial cells interact with several second messenger systems in a cell-specific manner.
Methods
Materials. Recombinant human IL-l a (rIL-1 ), and TNF were kindly provided by Drs. Peter Lomedico (Hoffmann-LaRoche, Nutley, NJ) 1 . Abbreviations used in this paper: DiOG, sn-1, 2-dioctanoylglycerol;
OAG, l-oleoyl-2-acetyl-sn-glycerol; PA, phosphatidic acid; PLA2, phospholipase A2; rIL-1, recombinant human IL-l a; TPA, tetradecanoyl phorbol 13-acetate.
and Leo Linn (Cetus Corporation, Emeryville, CA). Specific activities and endotoxin contents have previously been reported (9, 10, 16 PLA2 activity and mRNA levels. PLA2 activity was assayed in acid extracts of vehicle-and cytokine-treated mesangial cells exactly as we have published (9) . Briefly, mesangial cells cultured in 75 cm2 flasks were scrapped and homogenized in 0.18 N H2SO4 and 1 M NaCl, and the cleared supernatants were dialyzed overnight against 10 mM sodium acetate, pH 4.4. In some experiments, medium (0% FBS) was removed and centrifuged briefly at 12,000 g to remove cellular debris. The extracts and media were stored at -70°C until assay. PLA2 activity was assayed in vehicle and rIL-l -treated mesangial cell homogenates (15-30 ,ug protein) and media (50 gl) using exogenous [14C]-arachidonyl-phosphatidylethanolamine (final concentration, 16 JIM) as substrate in the presence of 100 mM Tris HCl, pH 8.5, and 2.5 mM CaCl2 for 60 min at 37°C. Hydrolyzed arachidonic acid was separated from the phospholipid substrate using silica gel thin layer chromatography. The characteristics of PLA2 activity released into the medium are identical to those we have reported for acid-extracted activity (9) . Released PLA2 activity is calcium-dependent (99% reduction by inclusion of 10 mM EGTA in the assay buffer), is inhibited by greater than 85% by 100 mM p-bromophenacyl bromide and represents more than 90% of the combined acid extractable and secreted PLA2 activity. Results presented in the figures are shown as the mean±SEM value ofduplicate determinations from the indicated number of experiments.
Northern analysis of total cellular RNA (25 Mg) from vehicle-and rIL-1 stimulated cells was used to size the PLA2 as previously described (5, 9, 17) . Total mesangial cell RNA was extracted using 4 M guanidine isothiocyanate and purified by ultracentrifugation through a cesium chloride cushion. Rat spleen RNA was concurrently analyzed as a positive control. The filters were hybridized at 42°C overnight with a full length PLA2 cDNA probe (2 ng/ml, provided by Dr. Hiroshi Teraoka, Shionogi and Co, Ltd, Osaka, Japan) labeled by nick translation. The membranes were subsequently washed for 30 min at room temperature with 2 X SSPE (1 x SSPE:180 mM NaCl, 10 mM Na2 HPO4-7H20, and 1 mM EDTA), for 30 min with 2 X SSPE, 2% SDS at 50°C, and for 15 min with 0.1 X SSPE, 1% SDS at 52°C. Autoradiograms were obtained by exposing the blots to Kodak XAR-5 film overnight. Transcript size (kb) was derived from an mRNA ladder of known fragment sizes (Bethesda Research Laboratories, Gaithersburg, MD). The filters were stripped and rehybridized with a 32P-labeled chicken a-tubulin cDNA probe. IL-6 mRNA expression was also assayed using the hybridization conditions described above. A 32P-labeled 650 bp cDNA fragment from murine IL-6 (gift from Dr. Steven Clark, Genetics Institute, Cambridge, MA) was used as a probe in some studies.
PLA2 mRNA abundance was assessed by RNA-RNA solution hybridization as we have previously described in detail (9) . Briefly, T7
RNA polymerase was used to synthesize a [32PlcRNA probe using a Pvu Il-linearized DNA template that contained a cDNA sequence (bp 381-758) for rat splenic, nonpancreatic (Type II) PLA2. A heterogenous nucleotide residue found in position 461 of the mature PLA2 RNA transcript produces protected transcripts of both 377 nucleotide and 297 nucleotide (9) . For this study, we have constructed, by standard methodologies, an additional DNA template that contains bp 666-759 of the PLA2 cDNA. T7 RNA polymerase was used to synthesize a 340 nt 32P-labeled probe from this template, which, when hybridized to total cellular RNA, protected a 93 nt transcript. Total mesangial cell RNA and the indicated probes were hybridized at 49°C overnight. Following hybridization, unprotected single stranded RNA was digested using RNAse A (50 ,g/ml) and Tl (2 ,g/ml) for Dupont-NEN] ) to the freshly isolated nuclei. In some cases, the nuclear preparations were preincubated with a-amanitin (1 Mg/ml) for 10 min before the start of the transcription assay. After 60 min at 28°C, the reaction was terminated by the addition of 100 U of DNase I in 300 mM NaCI, 30 mM MgCl2, 1.2 mM CaCI2, and 6.0 mM Tris, pH 7.4. This suspension was treated subsequently for 30 min at 37°C with proteinase K (200 Mg) in 1% SDS, 5 mM EDTA, and 10 mM Tris, pH 7.4, (1 X SET), extracted with phenol/ chloroform/ isoamyl alcohol and precipitated overnight at 20°C with isopropanol. The precipitate was resuspended in 50 Mul of 1 X SET and centrifuged through a G-25 Sephadex spin column (Quick Spin; Boehringer Mannheim Biochemicals). The purified RNA was subjected to limited base hydrolysis in 0.2M NaOH for 7 min at 4°C, neutralized with 0.48 M Hepes (free acid), and reprecipitated. Greater than 90% of the [32P]cpm were precipitated with 10% trichloroacetic acid. The resulting pellet was resuspended in 10 mM N-tris [hydroxymethyl]methyl-2-aminoethane sulfonic acid (TES), pH 7.4, 10 mm EDTA, 0.2% SDS, and 0.3 M NaCl (TES/ NaCl). Equivalent radioactive RNA (5 x 106 cpm) in 1 ml of TES/ NaCi were hybridized for 72 h at 650C with the indicated linearized plasmid DNAs (7.5 gg) bound to nitrocellulose filters. The plasmids used in these experiments were PLA2 (a full-length Type II PLA2 cDNA cloned into pGEM3Z), IL-6 (a 601 bp murine cDNA probe cloned into pXM, a gift ofGenetics Institute), pRGAPDH-l (a 1.3 kb rat glyceraldehyde-3-phosphate dehydrogenase [GAPDH]cDNA cloned into pBR322), and a control plasmid, pBR322. After hybridization, the filters were washed twice in 2 x SSC at room temperature, 3 times in 2 X SSC at 650C for 30 min, and then incubated with RNase A (10 ;tg/ml) at 370C for 30 min. The filters were washed subsequently in 2 x SSC/0.2% SDS at 650C for 30 min, rinsed in 2 x SSC, and exposed forautoradiography. Hybridized nuclear [32P] PLA2and [32p ]_ GAPDH abundance transcript was quantitated using a scanning densitometer (Scan Maker, Microtek, Torrance, CA) and appropriate software (Adobe Photshop, Adobe Systems, Mountain View, CA; and Scan Analysis Biosoft, Cambridge, UK) and corrected for backgrounds (counts hybridized to pBR322 or a-amanitin-insensitive counts hybridized to plasmid). PLA2 transcription rates were determined from the changes in PLA2/GAPDH mRNA ratios assessed under control and IL-l-stimulated conditions.
Message stability assay. Mesangial cells were incubated in 5% FBS media in the presence of rIL-I ( 10 ng/ml) for 24 h, the time of maximal PLA2 mRNA induction by IL-1. Actinomycin D (5 Mg/ml) was added to some dishes. Since certain mRNAs are stabilized in the presence ofIL-1 ( 19) , media containing IL-1 was removed from some cells before the addition of actinomycin D. Cells from each experimental protocol were harvested at the indicated times. Total cellular RNA was prepared and analyzed by Northern blotting for PLA2 mRNA expression. In some experiments, mesangial cells were stimulated with IL-1 in the absence of serum. However the presence or absence of serum had no independent effect on PLA2 mRNA turnover, and results from both experimental conditions have been pooled. In some experiments, the blots were rehybridized with the a-tubulin probe, and T1/2 for tubulin mRNA was determined from a first-order decay plot.
Results
Proinflammatory cytokines induce the expression ofa nonpancreatic PLA2 in mesangial cells. We first characterized the induction of PLA2 mRNA and enzyme expression by rIL-1. As shown in Fig. 1 , mesangial cells incubated in 5% FBS in the presence of rIL-1 (10 ng/ml) express a single 1.0 kb PLA2 mRNA transcript (Fig. 1 A) . The PLA2 transcript was detectable by 6 h of incubation with rIL-l. Transcript abundance increased with time and reached a plateau after 16 h (Fig. 1 B) . In 24 hour incubations, rIL-1 induced a dose-dependent, coordinate increase in PLA2 mRNA and activity ( Fig. 1 C, Table I ). The threshold concentration for rIL-l stimulated PLA2 expression was 1.0 ng/ml. The rIL-1-induced increase steady state PLA2 mRNA was not affected by coincubation with cycloheximide for two (not shown), four (not shown), or 24 h (Fig. 2  A) . Neither message abundance nor the kinetics of PLA2 mRNA induction were altered, suggesting that this transcript is not superinduced or rapidly degraded. Inclusion of actinomycin D did abolish the rIL-l induced gene expression (Fig. 2 B) , consistent with its effect on the PLA2 activity measured previously in acid extracts (9) .-Taken together, these data suggest that the rIL-I stimulated PLA2 activity requires de novo RNA synthesis that results in the coordinate synthesis and secretion of enzyme.
We next determined whether the IL-I-induced increase in PLA2 mRNA levels was in fact due to enhanced transcription, increased mRNA stability or both. Fig. 3 A shows a representative run-offtranscription analysis which demonstrates that rIL-1 increased the rate of PLA2 mRNA transcription. In three separate experiments, analysis of PLA2 nuclear transcript abundance, corrected for background and normalized for changes in GAPDH transcripts, indicated that PLA2 transcription rate increased 219±18% in cells stimulated with IL-l for 15 h compared to cell incubated with vehicle. The rIL-l-stimulated increase in PLA2 transcription rate was suppressed by concentrations of a-amanitin that specifically inhibit polymerase II activity (not shown). We also examined whether IL-l also had an effect on PLA2 RNA turnover (Fig. 3 B) . In the presence of actinomycin D, PLA2 mRNA degradation is exceeding slow, a finding which was unaffected by the presence of IL-1 in the incubation medium. In contrast, the half-life of tubulin transcripts in the same cells was 3 h, a decay rate similar to that reported for this mRNA in other cell lines (20) . h was analyzed as described for graph B. PLA2 activity in the medium was measured as described in Methods and is shown in parenthesis as the relative stimulation above the control value ( 1.0). Actual control and rIL-I stimulated mean PLA2 activities are shown in Table I . These data demonstrate that IL-I -stimulated increases in steady state PLA2 mRNA abundance resulted from a two-tothree-fold increase in the PLA2 transcription rate that is amplified by the prolonged persistence of the transcript. Although the lack of PLA2 mRNA degradation is striking, agonist stimulated accumulation of other mRNAs have been reported to result from a similar mechanism (20) . To better define the potential role of PLA2 in immune-me- Fig. 4 . TNF, rIL-1 a, and rIL-g markedly stimulated PLA2 message expression. LPS was less potent while IL-2 had no effect. As indicated, enzyme activity released into the medium (Fig. 4 , Table I ) was coordinate with mRNA induction. In addition, neither PDGF (see below) nor epidermal growth factor (not shown) stimulated mesangial cell PLA2 expression.
Forskolin and dibutyryl cAMP potentiate but do not mediate rIL-I-stimulated PLA2 expression. We are interested in defining the pathways used by IL-I in mesangial cells to activate a change in cellular function. IL-1 induces cAMP accumulation in some cells, and PLA2 activity has been reported to be stimulated by cAMP-elevating agents in vascular smooth muscle cells (21 ), astrocytes (22) , and rat mesangial cells (23) . We therefore examined the effect of forskolin and dibutyryl cAMP on PLA2 gene expression and PLA2 activity. As shown in Fig. 5 A, addition of forskolin (10 gM) significantly enhanced IL-1-induced PLA2 message expression by nearly fourfold (360±41% stimulation, mean±SEM, n = 3 individual experiments, P < 0.02). Similar results were obtained for a permeable cAMP analog, dibutyryl cAMP (1 mM) (Fig. 5 B) . The amount of PLA2 activity in the medium reflected the degree of mRNA expression (Fig. 5 , Table I ). In contrast, neither forskolin nor dibutyryl cAMP alone induced PLA2 gene expression (Fig. 5) or release of enzyme activity (Table I ). The inactive forskolin analog 1, 9-dideoxyforskolin, (10 ,uM), butyrate (0.2 mM), and dibutyryl cGMP (1 mM) also failed to potentiate the IL-1 response (data not shown). Taken together, these results suggest that activation of protein kinase A potentiates but does not mimic IL-1-stimulated mesangial cell PLA2 expression.
Diradylglycerols, phosphatidic acid, and phorbol ester do not mimic or alter rIL-J-induced PLA2 expression. We and others have shown that several lipid signals are rapidly formed in IL-1-stimulated mesangial cells, including 1 ,2-diacylglycerol and phosphatidic acid (10, 11) . As shown in Fig. 6 A, addition of diacylglycerol analogs, DiOG (100 ,uM) or OAG (50 ,g/ml), did not stimulate PLA2 gene expression or enhance phospholipase A2 activity in the medium (Table I) . Phosphatidic acid (50 ,ug/ml) also failed to stimulate PLA2 expression (Fig. 6 B) . The protein kinase C activator TPA also did not increase mesangial cell PLA2 mRNA or enzyme activity ( Fig. 6 B and Table I ) or alter rIL-1-induced PLA2 synthesis when it was coincubated with the cytokine (data not shown). These observations indicate that the effects of IL-I on the mesangial cell are not mediated or modified by the activation of protein kinase C. Consistent with this supposition, we have also shown by two-dimensional gel electrophoresis that rIL-l does not increase the phosphorylation state of the putative 80 kD substrate of protein kinase C (data not shown).
Serum modulates IL-I-stimulated PLA2 expression. Serum markedly alters mesangial cell PGE2 synthesis in response to rIL-1 (9), in part due to the action of serum on prostaglandin endoperoxide synthesis expression (24) . We have now assessed the role of serum on IL-1 stimulation of PLA2 gene expression and activity. As shown in Fig. 7 A, steady state PLA2 message levels in cells incubated with rIL-1 in the absence ofserum were two-fold higher than those observed with rIL-in serumtreated cells (209%+27%, mean±SEM, n = 3 individual experiments, P < 0.05). PLA2 activity measured in acid-extracts from serum-stimulated and serum-deprived, rIL-1-stimulated mesangial cells was concordant with mRNA expression (Fig. 7  B) . In cells coincubated with 5% FBS and rIL-1, PLA2 activity was 220±38 fmol /,ug per hr compared to rIL-1 stimulated activity in the absence of serum of 590±28 fmol/ug per hr, (mean±SEM). The presence or absence of serum alone in did not significantly alter PLA2 activity in acid extracts of mesangial cells. To assess whether the effect of serum on genes induced by rIL-1 was specific for PLA2, we also studied IL-l -stimulated IL-6 gene expression in the presence and absence of FBS. In contrast to its inhibitory action on PLA2 expression, serum did not inhibit IL-6 steady state mRNA levels (data not shown). The inhibitory effect of serum on PLA2 message appears to be specific and not due to an alteration in IL-I bioactivity, receptor expression or responsiveness of the cells to cytokine.
We next examined potential mechanisms by which serum could regulate IL-1-stimulated PLA2 expression. Serum contains a number of biologically active compounds, including hormones and growth factors. The synthetic glucocorticoid dexamethasone has been shown previously to inhibit PLA2 activity and the expression of other IL-I-stimulated mRNAs and proteins (25) . However, coincubation of mesangial cells with rIL-1 and dexamethasone did not significantly change PLA2 mRNA abundance or activity when compared to cells exposed to rIL-1 alone (Fig. 8 A and Table I ).
Several growth factors in serum activate receptor protein tyrosine kinases. The effect of the tyrosine kinase inhibitor, genistein, on cytokine-stimulated mesangial cell PLA2 mRNA expression is shown in Fig. 8 B. Genistein ( 10 ,tg/ml) markedly increased rIL-1-stimulated message -accumulation in serum-stimulated RMC compared to vehicle (444±12% stimulation, mean±SEM, duplicate experiments). Genistein at this concentration had no effect on cell viability as assessed by an assay of mitochondrial respiration (9) . The growth factor PDGF is an abundant constituent of serum, activates a receptor tyrosine kinase, and is a potent mesangial cell mitogen and a mediator of glomerular injury. PDGF (25 ng/ml) alone did not stimulate PLA2 mRNA synthesis or enzyme activity in serum-deprived cells but mimicked the effect of 5% FBS on IL-l-induced PLA2. When cells were coincubated with PDGF and IL-1, PLA2 transcript abundance was reduced by 72±8%, (mean+SEM, duplicate experiments). PDGF also attenuated the IL-l-stimulated PLA2 activity released in the media by 44%±9 (Table I) . Taken together, these data suggest that IL-l-stimulated PLA2 expression can be regulated by growth factor activation of receptor tyrosine kinases. rIL-13 (50 ng/ml), LPS (10 gg/ml), or IL-2 (1,500 U/ml) for 24 h. PLA2 message PLA2 activity |10 |52 78.1 was quantitated using RNA-RNA solution hybridization using the probe described in Fig. 2. (B PLA2 activity probe used was transcribed from a cDNA template that contained the sequence (bp 666-759) of rat spleen nonpancreatic (type II) PLA2 (see Methods). PLA2 activity released into the medium in response to the indicated stimulus was quantitated and normalized as described in Fig. 1 , and is expressed under the appropriate lane in each panel. Actual PLA2 activities for the condition in A and B are shown in Table I . Discussion IL-I and TNF activate mesangial cells to express new structural and functional characteristics, a process which involves specific changes in gene activity in the nucleus. We have studied regulation of a nonpancreatic (Type II) PLA2 to understand the intracellular pathways engaged in cytokine-activated mesangial cells. PLA2 expression provides a reasonable model system for defining mechanisms of transcriptional induction by IL-1 in mesangial cells, since we have shown this gene is transcriptionally regulated by IL-I, and that it is not detectable in quiescent, serum-stimulated, or growth factor-activated cells.
The basis for the specificity in gene induction by particular polypeptide ligands is poorly understood. In this study, we have used second messenger mimics to explore the intracellular pathways used by IL-1 to stimulate gene transcription. Our data show that protein kinase C activation (this paper), cAMP accumulation (this paper, reference 14), or rapid changes in cytosolic Ca2+ or pHi (10) ways are engaged directly by IL-1 to induce PLA2 mRNA expression. Since PLA2 gene expression is cycloheximide insensitive, we believe these signals ultimately activate transcription factor(s) by posttranslational modifications. Several mechanisms can be proposed to describe how IL-1-IL-I -receptor interactions directly alter gene activity in the nucleus. Traditional models of transmembrane signaling propose that a limited number of second messengers convey the information generated by a ligand-receptor interaction. Using this model in conjunction with published information describing IL-1-activated transmembrane signaling pathways (2, 10-14), we would suggest that IL-I alters the phosphorylation state ofa transcriptional factor or transcription factor complex by activating a kinase cascade. IL-1 can change protein phosphorylation patterns by activating extracellular signal-related kinase/ mitogen-activated peptide kinase (ERK/MAP kinase) (26, 27) or by inhibiting phosphatase activity (28) . Recent data suggest phosphorylation state can regulate transcriptional factor activity. Both c-jun and CREB are positively regulated by phosphorylation (29, 30) . Translocation ofthe rel/kfl proteins The signal intensities of the protected fragments for * each mRNA species were quantitated by densitome- 90 try, and the PLA2 mRNA expression was corrected for changes in the tubulin transcript abundance. Relative mesangial cell PLA2 mRNA expression after rIL-1-stimulation was arbitrarily defined as 100 units.
Released PLA2 activity was quantified and expressed as described in Fig. 1. ( were incubated for 24 h with rIL-I ( 10 ng/ml), PA (50 Mg/ml) or TPA (0.1 M) and analyzed for PLA2 and tubulin mRNA expression as described in A, except the probe described in Fig. 3 
U
In both A and B relative PLA2 activity in the medium is presented as previously described in Fig. 1 . Actual PLA2 activities for the conditions shown in A and B | 164.5 | . | I |are in Table I. to the nucleus requires phosphorylation of associated inhibitory proteins, which tether them in the cytosol (31 ) . In this model, specificity of gene induction by IL-1 results from unique interactions between activated transcription factors.
Recent work, which describes the pathways used by interferon-a/,3 to induce gene expression, suggests an alternative model (32) (33) (34) . Treatment with dexamethasone (Dex, 1 AM) or vehicle in the presence or absence of rIL-1 (10 ng/ml). Mesangial cell PLA2 mRNA expression was analyzed using the probe described in Fig. 3 B. (B) Mesangial cells were incubated in 5% FBS, and treated with genistein (10 ,ug/ml) or vehicle 30 min before the addition of rIL-1 ( 10 ng/ml) or vehicle. Parallel studies confirmed this concentration of genestein blocked growth factor activated receptor tyrosine kinase activity. Both PDGF-stimulated tyrosine phosphorylation, as determined by immunoblotting, and mesangial cell mitogenesis, as assessed by [3H]-thymidine incorporation and cell counts, were inhibited. Cellular RNA was harvested after 24 h and PLA2 and tubulin message were analyzed as previously described. (C) Cells were serum-restricted for 3 d then incubated with PDGF (25 ng/ml), rIL-l (10 ng/ml), or both for 24 h. Total RNA was isolated and analyzed for PLA2 and tubulin message as previously described. mesangial cell PLA2 mRNA expression and enzyme activity but not IL-6 mRNA expression. This specificity in the effect of serum suggests the mechanism does not involve an inhibitor of IL-I present in FBS (36) or the down-regulation of IL-1 receptors by chronic protein kinase C activation (37) . Genistein, a relatively selective inhibitor of tyrosine kinase activity at the concentration employed, however, enhances IL-1-stimulated PLA2 mRNA expression in serum-stimulated cells. Growth factor-activated receptor tyrosine kinases may mediate the effect ofserum on PLA2 mRNA abundance. Consistent with this hypothesis, coincubation of mesangial cells with PDGF and IL-1 reproduces the effect of serum on PLA2 expression. Although PDGF also stimulates protein kinase C activity, neither TPA nor diacylglycerol analogues reduce IL-1-stimulated PLA2 mRNA formation. Two recent studies have reported also that PDGF reduces PLA2 protein synthesis (38, 39) . Our results demonstrate this inhibition occurs at the level of mRNA abundance. Growth factors such as PDGF may counter-regulate the proinflammatory actions of cytokines. PDGF inhibits cytokine-stimulated synthesis of the complement protein Factor B, and potentiates IL-1-stimulated production of metalloproteinases in human fibroblasts through changes in mRNA abundance (40, 41) . Secretory Group II PLA2 promotes inflammatory injury (42) . Growth factor-dependent, down-regulation of PLA2 secretion may act to limit tissue destruction and shift the local balance to favor healing and tissue repair.
Recently a high molecular weight intracellular PLA2 (cPLA2), that is mechanistically and biochemically distinct from the Type II 14-kD PLA2 we have studied, has been described in the mesangial cell (42, 43) . We and others have demonstrated that within minutes IL-1 activates cPLA2 by phosphorylation2 (44, 45) . However, the precise function of each isoform in arachidonate metabolism and mesangial cell function and glomerular inflammation remains to be defined. Some, but not all studies, have suggested that activation ofboth isoforms results in arachidonic acid hydrolysis (42, (45) (46) (47) . The 14-kD, secreted PLA2 may be targeted to the cell membrane to hydrolyze phospholipids, an action that fails to irreversibly injure the cell (46, 47) . A regulatory mechanism must prevent lethal cell injury to allow the low molecular weight PLA2s to alter cell function independently of membrane disruption.
Both in vitro and in vivo studies suggest the mesangial cell expresses distinct phenotypes in response to changes in the glomerular microenvironment. Regulation of the Type II PLA2 gene presents a useful model for understanding how regulatory proteins and intracellular signaling pathways fit together to determine mesangial cell fate. Future work on this model system hopefully will discriminate the distinctive signaling pathways used by the mesangial cell for specialized responses to cytokines and provide insight in kidney-specific mechanisms of gene expression.
